The U.S. Food and Drug Administration (FDA) is considering how its existing medical device framework should apply to products that use generative artificial intelligence (GenAI).
In a recent discussion paper, FDA describes the unique characteristics of GenAI-enabled medical devices and asks the industry for input on how these products should be evaluated, monitored and modified over time.
Learn more about FDA's engagement with Generative AI and implications for companies.